Bivalirudin versus heparin in high and low bleeding risk patients undergoing primary PCI for STEMI: pre-specified analysis from the BRIGHT-4 trial
30 August 2026 (13:45 - 13:55)
Organised by: 

Abstract
About the speaker

General Hospital of Northern Theater Command, Shenyang (China)
5 More presentations in this session
Assistant Professor K. Leemasawat (Chiang Mai, TH)
Access the full session
The Event
ESC Congress 2026
30 August 2026
13:45 CET
You may be interested in
Congress Presentation
Congress Presentation
Congress Presentation


